The FOXFIRE Combined Analysis did not reach its primary endpoint of an overall survival (OS) benefit for patients treated with SIRT plus first-line chemotherapy compared to patients treated with chemotherapy alone1. However, the study has significantly enriched scientific understanding of the role of SIRT in the management of mCRC, particularly in the liver, which is the organ of greatest risk and the ultimate cause of death for the majority of these patients.2-4
Adapted from Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
1. Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
2. Van de Eynde M et al. Rev Rec Clin Trials 2009; 4: 56–62.
3. Kennedy A et al. Int J Radiation Oncology Biol and Phys 2006; 65: 412–25.
4. Gibbs P et al. Colorect Cancer 2014; 3(4): 345–62.